Breaking
Friday, June 19, 2026

FDA News

🇺🇸 FDA Page 14

FDA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page

Track critical FDA approvals, regulatory updates, and policy shifts impacting drug development and market access in the US. Stay ahead of compliance.

Showing 157–168 of 391 articles

High impact NewsJun 2, 2026

Lilly and Gilead Drive Pharma M&A Surge: A Strategic Market Analysis

FDA · cancer · 7 min

Dr. Sarah Mitchell
High impact AnalysisJun 2, 2026

Candel's Prostate Cancer Drug: Long-Term Data Insights Ahead of FDA Filing

FDA · prostate cancer · 8 min

Dr. Sarah Mitchell
High impact AnalysisJun 2, 2026

White House Taps Amazon, GoodRx to Expand TrumpRx Generic Drug Access

FDA · 7 min

Dr. Sarah Mitchell
High impact AnalysisJun 2, 2026

Supreme Court Upholds Medicare Drug Price Negotiation: Implications for Pharma

FDA · 8 min

Dr. Sarah Mitchell
High impact AnalysisJun 2, 2026

Retro Biosciences Secures $1.8 Billion Valuation in Landmark Longevity Funding Round

FDA · longevity · 10 min

Dr. Sarah Mitchell
High impact NewsJun 2, 2026

FDA Approves Atezolizumab for ctDNA MRD-Positive MIBC: A New Era for Adjuvant Therapy

FDA · muscle invasive bladder cancer · 7 min

Dr. Sarah Mitchell
High impact AnalysisJun 2, 2026

FDA Leadership Vacuum: Navigating Uncertainty for Pharmaceutical Business Development

FDA · 9 min

Dr. Sarah Mitchell
Critical impact NewsJun 2, 2026

Inventiva Bolsters Executive Team Ahead of Lanifibranor Phase 3 Data

FDA · 8 min

Dr. Sarah Mitchell
High impact AnalysisJun 2, 2026

Eli Lilly Acquires Engage Bio to Advance Non-Viral Genetic Medicines

FDA · genetic medicines · 7 min

Dr. Sarah Mitchell
High impact AnalysisJun 2, 2026

Eli Lilly's Strategic Vaccine Acquisitions: A New Era in Infectious Disease

FDA · vaccine · 6 min

Dr. Sarah Mitchell
High impact AnalysisJun 2, 2026

Wave Life Sciences' Monthly Dosing Strategy for AATD: A Competitive Analysis

FDA · AATD · 10 min

Dr. Sarah Mitchell
High impact AnalysisJun 2, 2026

Amgen and Zai Lab Leadership Shifts: Strategic Implications for Pharma BD and Investors

FDA · neurology · 8 min

Dr. Sarah Mitchell